Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report. (Record no. 12601)

MARC details
000 -LEADER
fixed length control field 02034nam a22003857a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 230626s20232023 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 2234-943X
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.3389/fonc.2023.1134151 [doi]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code PMC10046803 [pmc]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 36998440
245 ## - TITLE STATEMENT
Title Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report.
251 ## - Source
Source Frontiers in Oncology. 13:1134151, 2023.
252 ## - Abbreviated Source
Abbreviated source Front. oncol.. 13:1134151, 2023.
253 ## - Journal Name
Journal name Frontiers in oncology
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2023
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2023
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Publication date 2023
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status epublish
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Medline status PubMed-not-MEDLINE
266 ## - Date added to catalog
Date added to catalog 2023-06-26
520 ## - SUMMARY, ETC.
Abstract Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a patient with stage IV LCNEC harboring a KIF5B-RET fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment. Copyright © 2023 Arora, Zaemes, Ozdemirli and Kim.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Indexing Automated
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Washington Hospital Center
656 ## - INDEX TERM--OCCUPATION
Department Hematology & Oncology Fellowship
656 ## - INDEX TERM--OCCUPATION
Department Internal Medicine Residency
656 ## - INDEX TERM--OCCUPATION
Department MedStar Georgetown University Hospital/MedStar Washington Hospital Center
657 ## - INDEX TERM--FUNCTION
Medline publication type Case Reports
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Arora, Aakriti
Institution Code MWHC
Program Internal Medicine Residency
Degree MBBS
Resident year Resident PGY 3
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Zaemes, Jacob
Institution Code MGUH
Program Hematology & Oncology Fellowship
Degree MD
Resident year Fellow PGY 5
790 ## - Authors
All authors Arora A, Zaemes J, Ozdemirli M, Kim C
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.3389/fonc.2023.1134151">https://dx.doi.org/10.3389/fonc.2023.1134151</a>
Public note https://dx.doi.org/10.3389/fonc.2023.1134151
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 06/26/2023   36998440 36998440 06/26/2023 06/26/2023 Journal Article

Powered by Koha